In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4961-4971

  Patel, Hetalkumar D ^a   Nikitin, Pavel ^a   Gesner, Thomas ^a,b   Lin, James J ^a   Barkan, David T ^a   Ciferri, Claudio ^b,c   Carfi, Andrea ^b,d   Yazdi, Tahmineh Akbarnejad ^a   Skewes Cox, Peter ^a   Wiedmann, Brigitte ^a   Jarousse, Nadine ^a   Zhong, Weidong ^a   Feire, Adam ^a   Hebner, Christy M ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Novartis Vaccines Cambridge   (United States)

^c GENENTECH INC   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; LPJ 538; LPJ 539; MONOCLONAL ANTIBODY; SEVIRUMAB; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DRUG POTENTIATION; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SYNCYTIUM; UMBILICAL VEIN ENDOTHELIAL CELL; VIRUS ISOLATION; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MUTATION; PATHOGENICITY; VIRUS ENTRY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84979581127     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00382-16     Document Type: Article

References (33)

1. Torres-Madriz G, Boucher HW. 2008. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 47:702-711. http://dx.doi.org/10.1086/590934.
2. Boeckh M, Ljungman P. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711-5719. http://dx.doi.org/10.1182/blood-2008-10-143560.
3. Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362. http://dx.doi.org/10.1056/NEJMoa043337.
4. Polilli E, Parruti G, D'Arcangelo F, Tracanna E, Clerico L, Savini V, D'Antonio F, Rosati M, Manzoli L, D'Antonio D, Nigro G. 2012. Preliminary evaluation of the safety and efficacy of standard intravenous immunoglobulins in pregnant women with primary cytomegalovirus infection. Clin Vaccine Immunol 19:1991-1993. http://dx.doi.org/10.1128/CVI.00509-12.
5. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G, CHIP Study Group. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316-1326. http://dx.doi.org/10.1056/NEJMoa1310214.
6. Sinzger C, Digel M, Jahn G. 2008. Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 325:63-83.
7. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023-10033. http://dx.doi.org/10.1128/JVI.78.18.10023-10033.2004.
8. Wang D, Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA102:18153-18158. http://dx.doi.org/10.1073/pnas.0509201102.
9. Zhou M, Lanchy JM, Ryckman BJ. 2015. Human cytomegalovirus gH/gL/gO promotes the fusion step of entry into all cell types, whereas gH/gL/UL128-131 broadens virus tropism through a distinct mechanism. J Virol 89:8999-9009. http://dx.doi.org/10.1128/JVI.01325-15.
10. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. 1992. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165:381-384. http://dx.doi.org/10.1093/infdis/165.2.381.
11. Wang D, Li F, Freed DC, Finnefrock AC, Tang A, Grimes SN, Casimiro DR, Fu TM. 2011. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29:9075-9080. http://dx.doi.org/10.1016/j.vaccine.2011.09.056.
12. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. 2012. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444-7447. http://dx.doi.org/10.1128/JVI.00467-12.
13. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005-1013. http://dx.doi.org/10.1128/JVI.01809-09.
14. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. 1995. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318.
15. Nokta M, Tolpin MD, Nadler PI, Pollard RB. 1994. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res 24:17-26. http://dx.doi.org/10.1016/0166-3542(94)90048-5.
16. Manley K, Anderson J, Yang F, Szustakowski J, Oakeley EJ, Compton T, Feire AL. 2011. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10:197-209. http://dx.doi.org/10.1016/j.chom.2011.07.010.
17. Ibig-Rehm Y, Gotte M, Gabriel D, Woodhall D, Shea A, Brown NE, Compton T, Feire AL. 2011. High-content screening to distinguish between attachment and post-attachment steps of human cytomegalovirus entry into fibroblasts and epithelial cells. Antiviral Res 89:246-256. http://dx.doi.org/10.1016/j.antiviral.2011.01.007.
18. Chou SW, Dennison KM. 1991. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 163:1229-1234. http://dx.doi.org/10.1093/infdis/163.6.1229.
19. Chou S. 1992. Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J Infect Dis 166:604-607. http://dx.doi.org/10.1093/infdis/166.3.604.
20. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA. 2001. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7:343-351. http://dx.doi.org/10.1016/S1083-8791(01)80005-7.
21. Spindler N, Diestel U, Stump JD, Wiegers AK, Winkler TH, Sticht H, Mach M, Muller YA. 2014. Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS Pathog 10:e1004377. http://dx.doi.org/10.1371/journal.ppat.1004377.
22. Chandramouli S, Ciferri C, Nikitin PA, Calo S, Gerrein R, Balabanis K, Monroe J, Hebner C, Lilja AE, Settembre EC, Carfi A. 2015. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat Commun 6:8176. http://dx.doi.org/10.1038/ncomms9176.
23. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B. 2011. HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7:e1001256. http://dx.doi.org/10.1371/journal.ppat.1001256.
24. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853-865. http://dx.doi.org/10.1099/vir.0.83523-0.
25. Vanarsdall AL, Ryckman BJ, Chase MC, Johnson DC. 2008. Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J Virol 82:11837-11850. http://dx.doi.org/10.1128/JVI.01623-08.
26. Jacob CL, Lamorte L, Sepulveda E, Lorenz IC, Gauthier A, Franti M. 2013. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology 444:140-147. http://dx.doi.org/10.1016/j.virol.2013.06.002.
27. Watzl C. 2014. How to trigger a killer: modulation of natural killer cell reactivity on many levels. Adv Immunol 124:137-170. http://dx.doi.org/10.1016/B978-0-12-800147-9.00005-4.
28. Atalay R, Zimmermann A, Wagner M, Borst E, Benz C, Messerle M, Hengel H. 2002. Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 76:8596-8608. http://dx.doi.org/10.1128/JVI.76.17.8596-8608.2002.
29. Cui X, Meza BP, Adler SP, McVoy MA. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766. http://dx.doi.org/10.1016/j.vaccine.2008.07.092.
30. Auerbach MR, Yan D, Vij R, Hongo JA, Nakamura G, Vernes JM, Meng YG, Lein S, Chan P, Ross J, Carano R, Deng R, Lewin-Koh N, Xu M, Feierbach B. 2014. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog 10:e1004060. http://dx.doi.org/10.1371/journal.ppat.1004060.
31. Schleiss MR, Buus R, Choi KY, McGregor A. 2013. An attenuated CMV vaccine with a deletion in tegument protein GP83 (pp65 homolog) protects against placental infection and improves pregnancy outcome in a guinea pig challenge model. Future Virol 8:1151-1160. http://dx.doi.org/10.2217/fvl.13.107.
32. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199. http://dx.doi.org/10.1056/NEJMoa0804749.
33. Prichard MN, Aseltine KR, Shipman CJ. 1993. MacSynergy II manual. University of Alabama at Birmingham, Birmingham, Alabama. http://www.uab.edu/images/pediatrics/ID/MacSynergy.pdf.